Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.
We have four products in late-stage development, with MED3000 and TPR100 being the lead products.
MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, and was developed specifically for the treatment of ED.
Concept
Development
Commercialisation
Desctiption: Topical gel for erectile dysfunction
Status: Phase 3 study completed. Regulatory submissions targeted for mid 2020. Out-licensing discussions ongoing.
Desctiption: Topical diclofenac pain relief gel
Status: Regulatory dossier submitted in the UK. UK licence partner addressing queries with support from Futura. Licensing discussions for further territories ongoing.
Concept
Development
Commercialisation
Desctiption: Topical Cannabidiol formulation
Status: Joint venture collaboration. Early development stage to explore a number of disease states including pain relief.
Desctiption: Condom containing an erectogenic gel
Status: Approved in the EU, 24 month shelf life